# EDGAR Filing Document

**Accession Number:** 0001840748
**File Stem:** 0000000000-23-000092
**Filing Date:** 2023-1
**Character Count:** 2729
**Document Hash:** 1481dbfc5690af2aa31e78d4e367e9e1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000092.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0000000000-23-000092

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230104

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LAVA Therapeutics NV
- **CENTRAL INDEX KEY:** 0001840748
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** YALELAAN 60
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM
- **BUSINESS PHONE:** 31 6 3000 3035

**MAIL ADDRESS:**
- **STREET 1:** YALELAAN 60
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAVA Therapeutics BV
- **DATE OF NAME CHANGE:** 20210115

## Text-Extract

```

United States securities and exchange commission logo

                      January 4, 2023

       Fred Powell
       Chief Financial Officer
       LAVA Therapeutics N.V.
       520 Walnut St, Suite 1150
       Philadelphia, PA 19106

                                                        Re: LAVA Therapeutics
N.V.
                                                            Form 20-F for the
Fiscal Year Ended December 31, 2021
                                                            Filed March 24,
2022
                                                            File No. 001-40241

       Dear Fred Powell:

              We have completed our review of your filings. We remind you that
the company and its
       management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding
       any review, comments, action or absence of action by the staff.

                      Sincerely,

                      Division of Corporation Finance

                      Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 4, 2023

Fred Powell
Chief Financial Officer
LAVA Therapeutics N.V.
520 Walnut St, Suite 1150
Philadelphia, PA 19106

Re: LAVA Therapeutics N.V.
Form 20-F for the Fiscal Year Ended December 31, 2021
Filed March 24, 2022
File No. 001-40241

Dear Fred Powell:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences